Premium
[P3–049]: SPINGOSINE‐1‐PHOSPHATE RECEPTOR 5 AGONIST α‐971432 IMPROVES LEARNING AND MEMORY IN THE SAMP8 MOUSE MODEL OF ALZHEIMER's DISEASE
Author(s) -
Farr Susan A.,
Louise van der Kam Elizabeth,
Brown Jordan W.,
Niehoff Michael L.,
Morley John E.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1862
Subject(s) - agonist , medicine , sphingosine 1 phosphate receptor , receptor , morris water navigation task , pharmacology , endocrinology , hippocampus , sphingosine , sphingosine 1 phosphate
dapagliflozin or vildagliptin equally improved brain mitochondrial function, brain insulin sensitivity and prevented cognitive decline. However, only dapagliflozin improved hippocampal synaptic plasticity. Surprisingly, combined drugs exerted greater efficacy in increased brain insulin sensitivity than monotherapy. All findings were concluded in table 1. Conclusions:Both vildagliptin and dapaglifozin share similar efficacy on improving brain mitochondrial function, brain insulin sensitivity and preventing cognitive decline in obese-insulin resistant rats. However, dapaglifozin exert better efficacy on the improvement of metabolic profiles and hippocampal synaptic plasticity than vildagliptin.